
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
AOD-9604 (UPA Platinum)
|
Category: |
Weight Loss / Metabolic / Longevity |
|
SKU: |
TRW-AOD9604 |
|
Price: |
R 395.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS AOD9604 5 | AOD-9604 5mg Self-Mix Vial
AOD 9604 5 (AOD9604 5mg) – Specialised fat metabolism peptide fragment designed to support targeted lipolysis and stubborn fat reduction. Pharmaceutical-grade 5mg vial kit with bacteriostatic water.
Product Overview
AOD 9604 5 is an AOD-9604 5mg self-mix vial. AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH), specifically residues 177–191 (also referenced as the 176–191 fragment in some literature).
It was engineered to retain the lipolytic (fat-breaking) activity of the parent hormone while lacking the growth-promoting and diabetogenic effects mediated through the hGH receptor and IGF-1 pathway.
How AOD-9604 Works: β3-Adrenergic Lipolytic Pathway
AOD-9604 does not compete for the hGH receptor and does not induce cell proliferation or increase IGF-1. Its mechanism is distinct from that of full growth hormone. Its lipolytic action is thought to involve the β3-adrenergic receptor (β3-AR) pathway, with chronic administration upregulating β3-AR RNA expression in adipocytes.
In rodent studies, AOD-9604 reduces lipogenesis (fat synthesis), increases lipolysis (fat breakdown), and enhances fatty acid oxidation, leading to decreased body weight in obese animals. The lipolytic effects of AOD-9604 are believed to depend, at least in part, on β3-adrenergic receptor signalling.
Body Recomposition Benefits
AOD-9604 targets fat metabolism at the cellular level rather than appetite regulation. It does not suppress hunger and does not affect gut motility. Its primary action is to promote fat oxidation while preserving lean muscle tissue, making it a unique tool for body composition rather than scale-weight reduction.
Unlike GLP-1 receptor agonists, which have been associated with muscle loss during weight reduction, AOD-9604 spares muscle catabolism while stimulating fat breakdown. This makes it particularly suitable for individuals seeking targeted fat loss without compromising lean mass, including those who have completed a GLP-1 protocol and wish to consolidate body recomposition results.
Titration Protocol
AOD-9604 is administered via subcutaneous injection. The standard research dosage range is 200–500 mcg once daily, with 300 mcg being the most commonly referenced starting dose in compounding practice.
Injections are typically administered in the morning on an empty stomach, before food or cardiovascular exercise, when insulin levels are lowest and sympathetic nervous system activity is naturally elevated.
A standard titration schedule is as follows:
· Weeks 1–2: 200 mcg once daily — establishes baseline tolerability.
· Weeks 3–6: 300–400 mcg once daily — mild step-up for increased lipolytic activity.
· Weeks 6–12: 300–500 mcg once daily — maintenance range; some protocols escalate to 500 mcg split into two doses (250 mcg AM and 250 mcg before bed) if results plateau after 4 or more weeks.
Cycles are typically run for 4–12 weeks, followed by a washout period. Within a cycle, dosing is usually daily, 5 or 7 days per week. Once reconstituted, the solution should be refrigerated at 2–8°C and used within 4 weeks. Do not freeze the reconstituted solution.
Combination Therapy
AOD 9604 is commonly stacked with other peptides in wellness and body recomposition protocols:
· GH secretagogues (CJC-1295 / Ipamorelin): AOD-9604 promotes fat-specific lipolysis without lean mass catabolism, while CJC-1295/Ipamorelin-stimulated GH/IGF-1 elevation promotes protein synthesis and muscle preservation. This combination targets both sides of body recomposition — fat loss and lean mass support.
· GLP-1 receptor agonists (retatrutide, tirzepatide, semaglutide): AOD-9604 is layered onto GLP-1 protocols at 250–300 mcg daily, fasted morning, to enhance fat mobilization and potentially mitigate muscle loss associated with incretin-based therapies.
· MOTS-c: Stacked with AOD-9604 for metabolic optimization, combining mitochondrial AMPK activation with β3-adrenergic lipolysis.
· BPC-157: The “Wolverine” stack combines AOD-9604 with BPC-157, targeting both body composition and tissue repair. BPC-157’s anti-inflammatory and healing properties may complement AOD-9604’s emerging cartilage-supportive effects, particularly for individuals with joint issues alongside body composition goals.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
AOD-9604 has been evaluated in human clinical trials for obesity. A 12-week multicenter Phase IIa trial (METAOD005) with 300 obese participants found that the 1 mg dose group lost an average of 2.6 kg more than placebo.
A separate 12-week study showed modest fat loss of 2.8 kg versus 0.8 kg for placebo at 1 mg daily. However, the pivotal Phase IIb trial did not achieve statistical significance for weight loss compared to placebo, and the obesity development program was discontinued in 2007.
These findings underscore that AOD-9604’s effects are modest when used as monotherapy, and its role in contemporary practice is primarily as a targeted adjunct within broader body recomposition protocols rather than as a standalone weight-loss agent.
Technical Specifications
· Product Name: AOD 9604 5
· Peptide: AOD-9604 (hGH fragment 177–191)
· Concentration: 5mg per vial
· Form: Self-mix vial
· Reconstitution: Requires bacteriostatic water for reconstitution
· Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. AOD 9604 5 is intended for use under professional medical supervision. AOD-9604 is not approved by the FDA or SAHPRA for human therapeutic use.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.